Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Cocilova

Nurse Practitioner, Family Flowood, MS Nurse Practitioner

NPI 1184038499 CMS profile 11045952

120 Stone Creek Blvd Ste 500, Flowood, MS 39232

Open in the dashboard

General payments

$72,487

504 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Cocilova of Flowood, MS is reported in the CMS Open Payments database as having received $72,487 across 504 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,533 105
2024 General $19,079 146
2023 General $15,517 118
2022 General $11,070 81
2021 General $2,289 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Cocilova
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashley Cocilova were reported at $24,533. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashley Cocilova Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,289 $124 $35–$379 $132
2022 $11,070 $141 $44–$430 $149
2023 $15,517 $154 $49–$476 $160
2024 $19,079 $165 $51–$504 $164
2025 $24,533 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $51,439 334 payments
  2. Spinal Simplicity, LLC $18,257 64 payments
  3. Boston Scientific Corporation $972 16 payments
  4. Medtronic, Inc. $540 29 payments
  5. AbbVie, Inc. $442 25 payments
  6. Relievant Medsystems, Inc. $335 6 payments
  7. Amgen Inc. $124 6 payments
  8. Biohaven Pharmaceuticals, Inc. $80 5 payments
  9. Collegium Pharmaceutical, Inc. $57 4 payments
  10. BIOTRONIK NRO, Inc. $42 2 payments
  11. Other $199 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $27,109 103 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,853 38 payments
  3. Food and Beverage $12,742 334 payments
  4. Consulting Fee $7,300 15 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $6,884 13 payments
  6. Education $1,600 1 payment
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $32,413 190 payments
  2. HA MINUTEMAN G3-R $18,257 64 payments
  3. PROCLAIM Structural Heart $4,101 18 payments
  4. PROCLAIM Neuromodulation $3,709 16 payments
  5. AXIUM $2,841 9 payments
  6. PROCLAIM Structural Heart $2,762 9 payments
  7. ETERNA Neuromodulation $1,667 39 payments
  8. Proclaim IPG $1,493 15 payments
  9. IonicRF $1,279 4 payments
  10. ETERNA Structural Heart $711 16 payments
  11. Other $3,613 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

4,681

Median for Nurse Practitioner: 389

Drug cost

$150,992

Median for Nurse Practitioner: $21,885

Branded share of claims

45.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 59 $45,633
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,160 $31,166
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 681 $22,326
Pregabalin Generic 363 $10,041
Gabapentin Generic 553 $7,941
Savella Milnacipran Hcl Brand 11 $5,220
Celecoxib Generic 87 $4,167
Morphine Sulfate Er Morphine Sulfate Brand 172 $3,816
Oxycodone Hcl Generic 163 $2,914
Tizanidine Hcl Generic 299 $2,496

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$152,788

Of which drugs: $23

Medicare patients

222

Average age 70

Services billed

2,727

148 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Depression 32%
Ischemic heart disease 27%
COPD 22%
Chronic kidney disease 21%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 32 $16
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 14 72 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

504 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record